Black Titan (NASDAQ:BTTC – Get Free Report) is one of 48 publicly-traded companies in the “Services – Computer Programming And Data Processing” industry, but how does it weigh in compared to its competitors? We will compare Black Titan to similar businesses based on the strength of its risk, valuation, dividends, profitability, analyst recommendations, institutional ownership and earnings.
Profitability
This table compares Black Titan and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Black Titan | N/A | -108.60% | -95.64% |
| Black Titan Competitors | -63.65% | -919.53% | -68.53% |
Valuation and Earnings
This table compares Black Titan and its competitors revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Black Titan | $180,000.00 | -$4.71 million | -0.54 |
| Black Titan Competitors | $248.23 million | -$55.65 million | -10.03 |
Analyst Recommendations
This is a breakdown of recent recommendations for Black Titan and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Black Titan | 1 | 0 | 0 | 0 | 1.00 |
| Black Titan Competitors | 99 | 204 | 221 | 14 | 2.28 |
As a group, “Services – Computer Programming And Data Processing” companies have a potential upside of 118.48%. Given Black Titan’s competitors stronger consensus rating and higher probable upside, analysts plainly believe Black Titan has less favorable growth aspects than its competitors.
Insider & Institutional Ownership
57.9% of shares of all “Services – Computer Programming And Data Processing” companies are held by institutional investors. 53.7% of Black Titan shares are held by insiders. Comparatively, 20.6% of shares of all “Services – Computer Programming And Data Processing” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Risk and Volatility
Black Titan has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, Black Titan’s competitors have a beta of 0.54, meaning that their average share price is 46% less volatile than the S&P 500.
Summary
Black Titan competitors beat Black Titan on 7 of the 13 factors compared.
About Black Titan
Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.
Receive News & Ratings for Black Titan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Titan and related companies with MarketBeat.com's FREE daily email newsletter.
